Safety assessments indicated that gastrointestinal adverse events, mainly nausea and diarrhea, had been dose-dependent but generally gentle and transient. These conclusions set up the therapeutic window and knowledgeable dose assortment for subsequent Stage 3 trials.Renal basic safety has become similarly reassuring. Across Stage 1–three trials,